Pro Medicus Limited (ASX: PME) has announced a series of senior management changes, effective 16 Mar 2026. The Pro Medicus corporate announcement marks a deliberate internal restructure, with two promotions confirmed and a new leadership layer added to support the Company’s growth ambitions.
Figure 1: Pro Medicus Limitedcor   porate logo [Courtesy: Pro Medicus]
The changes see a long-serving finance executive step into a broader operational role, while an internal successor steps up to take the helm as Chief Financial Officer. Chief Executive Officer Dr Sam Hupert described the moves as a reflection of the depth of talent within the team.
Leadership Restructure Reflects Succession Planning at Pro Medicus
Clayton Hatch Moves Into Dual Operational Roles
Pro Medicus has transitioned Clayton Hatch, who served as Chief Financial Officer since June 2012, into two newly created roles. He will now serve as Head of Business Operations and Head of Investor Relations simultaneously.
In his new capacity, Mr Hatch will oversee operational initiatives across the Company, with a focus on driving growth and enhancing productivity, performance, and profitability. He will also manage communications between the Company and its investor base.
Danny English Steps Up as Incoming Chief Financial Officer
Danny English has been appointed Chief Financial Officer, succeeding Mr Hatch in the role. Ms English joined the Company in March 2015 as Group Financial Controller and was subsequently promoted to Head of Finance and Company Secretary three years ago.
Figure 2: Danny English, incoming Chief Financial Officer of Pro Medicus Limited [Courtesy: LinkedIn]
Ms English brings extensive global financial management experience to the position. She has worked in senior finance roles in both London and New York, and carries a deep understanding of ASX financial reporting, governance, and risk management across both private and publicly listed companies.
CEO Dr Sam Hupert on the Pro Medicus Corporate Announcement
Promotions Recognised as Well-Deserved by Leadership
Dr Sam Hupert, Chief Executive Officer, offered his congratulations to both appointees on the occasion of this Pro Medicus corporate announcement. He described Mr Hatch’s transition as recognition of his deep knowledge of the Company’s operations and investor relationships.
Figure 3: Dr Sam Hupert, Chief Executive Officer of Pro Medicus Limited [Courtesy: AFR]
Dr Hupert noted that Ms English’s appointment to the role of Chief Financial Officer reflects the extensive financial expertise she has developed over many years. He added that the changes underscore the Company’s deliberate approach to succession planning.
Pro Medicus Reaffirms Its Strategic Objective
Dr Hupert stated that the restructure highlights the depth of talent within the Pro Medicus team. He expressed his intention to work closely with both appointees in their new roles.
The Company’s stated key objective remains being the leading provider of best-in-class enterprise medical imaging solutions. This Pro Medicus company news Australia reinforces that internal capability development is central to that long-term ambition.
About Pro Medicus Limited
Pro Medicus was founded in 1983 and has grown into a leading healthcare informatics company. The Company provides a full range of medical imaging software and services to hospitals, imaging centres, and health care groups worldwide.
In January 2009, Pro Medicus acquired Visage Imaging, transforming itself into a global provider of medical imaging solutions. Its Visage 7 suite of products forms the foundation of an ultra-fast, clinically rich, and highly scalable platform deployable across both public and private cloud environments. The Company holds offices in Melbourne, Berlin, and San Diego.
Industry Outlook
The global medical imaging software market continues to expand, driven by rising demand for cloud-based diagnostic platforms and artificial intelligence integration in clinical workflows. Pro Medicus company news Australia reflects a broader trend among ASX-listed health technology companies investing in leadership depth and governance structures to support international growth. Companies with end-to-end imaging capabilities, including RIS, PACS, and AI solutions, are increasingly well-positioned as health systems accelerate digital transformation.
Pro Medicus Share Price
Pro Medicus Limited (ASX: PME) is currently trading at A$131.900 per share. The Company carries a market capitalisation of A$13.95 billion. The 52-week range stands at A$107.750 to A$336.000 per share.
Figure 4: One-year share price chart of Pro Medicus Limited [Courtesy: ASX]
Future Direction and Impact
The appointments signal a maturing organisational structure at Pro Medicus, with clear succession pathways now in place at the executive level. The elevation of Danny English to Chief Financial Officer and the creation of Clayton Hatch’s dual roles suggest the Company is building the internal bandwidth needed to manage both growth and investor engagement at scale.
For those tracking who is Pro Medicus CEO and the broader leadership composition, the Company remains under the direction of Dr Sam Hupert. This Pro Medicus corporate announcement positions the executive team to pursue the Company’s objective of global leadership in enterprise medical imaging solutions.
Frequently Asked Questions
Q1. Who is Pro Medicus CEO as of 2026?
Ans. Dr Sam Hupert continues to serve as Chief Executive Officer of Pro Medicus Limited (ASX: PME). He congratulated both appointees in the Company’s senior management announcement released on 16 Mar 2026.
Q2. What did the Pro Medicus corporate announcement on 16 Mar 2026 confirm?
Ans. The announcement confirmed that Clayton Hatch has moved from Chief Financial Officer into two newly created roles as Head of Business Operations and Head of Investor Relations, and that Danny English has been appointed as the incoming Chief Financial Officer.
Q3. What is Danny English’s background at Pro Medicus?
Ans. Danny English joined the Company in March 2015 as Group Financial Controller. She was later promoted to Head of Finance and Company Secretary. She holds senior finance experience from roles in London and New York.
Q4. What are Clayton Hatch’s new responsibilities at Pro Medicus?
Ans. Clayton Hatch will oversee operational initiatives across the Company in his role as Head of Business Operations. As Head of Investor Relations, he will manage communications between the Company and its investors.
Q5. Why does this Pro Medicus company news Australia matter to investors?
Ans. The restructure signals that Pro Medicus has a defined succession framework in place. The internal promotions reflect leadership stability at one of the ASX’s most closely watched health technology companies, with a market capitalisation of A$13.95 billion.
Disclaimer
This article is intended for informational purposes only and does not constitute financial or investment advice. All content is based on the ASX announcement released by Pro Medicus Limited on 16 Mar 2026, authorised by the Board of Pro Medicus Limited. Investing in securities involves risk, including the possible loss of principal. Readers should conduct their own research and seek independent financial advice before making any investment decisions. Colitco does not hold any position in the companies mentioned.
Sources
Pro Medicus Limited — ASX Announcement: Senior Management Appointments, 16 Mar 2026 https://data-api.marketindex.com.au/api/v1/announcements/XASX:PME:3A689473/pdf/inline/senior-management-appointments?_gl=1*1soo8fq*_ga*MTcwODQzODA4Ni4xNzYyMjUxMTk2*_ga_R504V9JPBH*czE3NzM2MTk5NDYkbzkzJGcwJHQxNzczNjE5OTQ2JGo2MCRsMCRoMA..
ASX Market Data — Pro Medicus Limited (ASX: PME) https://www.asx.com.au/markets/company/PME
